Read on Twitter
#Whycmr substudy of #EXPLORER #HCM ( #mavacamten vs #placebo ) presented by @S2beri @AHAMeetings #AHA2020 ---- follow along and read the paper in @CircAHA
#Cardiotwitter
#Cardiotwitter
Background on why #mavacamten and its effect on myosin-actin interaction and hypercontractility
Design of the study -
#whycmr at baseline and at week 30
no devices
Primary endpoint - LV mass , many other exploratory
#whycmr at baseline and at week 30
no devices
Primary endpoint - LV mass , many other exploratory
n= 35
Baseline characteristics - reminder, this was a substudy of an RCT
Baseline characteristics - reminder, this was a substudy of an RCT
over 30 weeks - nice results on positive remodeling - take a deeper dive into the numbers
Effect on LVEF, MCF (making @MathewMaurer proud) , and volumes
2 patients example
Also looked at ECV , LGE
Correlation between LVMI and hs-cTnI reduction
For #mavacamten
-- improve pVo2
-- improve how patients feel
-- improve echo findings
-- and now improve structure/favorable remodeling on #whycmr
and more to come from the OLE phase on long term effect
-- improve pVo2
-- improve how patients feel
-- improve echo findings
-- and now improve structure/favorable remodeling on #whycmr
and more to come from the OLE phase on long term effect
It starts and ends with patients
Read the paper here https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.052359
or here
Key figure
